Phase 2
N=24
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Bottom Line
View on ClinicalTrials.gov: NCT02278562 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcome: Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- anakinra (Drug); actos (Drug); placebo (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Mar 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Leucine Disposal Rate (LDR) |
-0.011; 0.005; 0.001 | 0.37 |
| SECONDARY Change in Whole-body Net Protein Balance |
-0.184; -0.215; 0.018 | — |
| SECONDARY Change in Skeletal Muscle Net Protein Balance |
-5.1; 11.8; 134.1 | — |
Summary
By 2030 an estimated 2 million people in the US will need dialysis or transplantation for advanced kidney failure. An even more disturbing statistic is that mortality in End Stage Renal Disease (ESRD) is six times higher than in the general Medicare population with adjustment for age, gender and ethnicity. Protein energy wasting is highly prevalent in these patients and is one of the most important determinants of their poor clinical outcome.
Despite its well-recognized occurrence, the etiology and the mechanisms leading to protein energy wasting observed in chronic hemodialysis patients cannot be attributed to any single factor. However, irrespective of the specific etiologic mechanisms, it appears that the common pathway for all the metabolic derangements is related to exaggerated protein degradation relative to protein synthesis (47).
Two well-recognized and presumably interrelated metabolic abnormalities, insulin resistance and chronic inflammation, may be the major determinants of protein catabolism in coronary heart disease (CHD) patients. There are no studies examining the effects of anti-inflammatory interventions and/or insulin sensitizers on protein homeostasis in CHD. Due to their established anti-inflammatory and other pleiotropic effects, Interleukin-1 receptor antagonist Anakinra and insulin sensitizer peroxisome proliferator-activated receptors (PPAR) agonist Actos represent two such promising interventions. By modulating inflammatory response and insulin signaling through two pharmacological interventions, the investigators will have the unique opportunity to clarify mechanisms contributing of these two particular metabolic derangements in the development of protein energy wasting observed in chronic hemodialysis patients.
The overall goal is to elucidate the mechanisms by which chronic inflammation and insulin resistance influence the development of protein energy wasting in hemodialysis patients.
Specific Aim: To test the hypothesis that inhibiting inflammatory response by administration of an Interleukin1receptor antagonist (Anakinra) or increasing insulin sensitivity by administration of a PPAR agonist (Actos) will improve net protein metabolism.
Hypothesis: The chronic inflammatory component of protein energy wasting (PEW) observed in hemodialysis patients is, at least in part, mediated by insulin resistance.
Interim analysis may be performed (no specific plan at this time).
Eligibility Criteria
Inclusion Criteria
- Patients on CHD undergoing three time a week therapy for more than 6 months;
- Age 21 years old;
- Acceptable dialysis adequacy (spKt/V > 1.2);
- A patent, well-functioning, arterio-venous dialysis access;
- Ability to give informed consent;
- Life expectancy greater than 6 months;
- BMI >=20 and 5 mg/day; excluding inhaled and topical steroids);
- Diabetes Mellitus on insulin therapy;
- Previous history of tuberculosis (TB) with or without documented adequate therapy;
- Patients with recent close exposure to an individual with active TB;
- Females using oral contraceptives;
- Patients with New York Heart Association (NYHA) Class III or IV heart failure;
- Patients with a history of angina, myocardial infarction, transient ischemic attacks, or strokes within the last 6 months.
Data sourced from ClinicalTrials.gov (NCT02278562). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.